POLPHARMA-BIOLOGICS
21.1.2021 10:43:11 CET | Business Wire | Press release
European biotechnology company Polpharma Biologics has unveiled a new logo and corporate message as part of an extensive rebranding initiative.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005383/en/
Dr Joerg Windisch, CEO of Polpharma Biologics, said “Our new brand represents our passion and dedication to innovation, we utilize the latest technology and cutting-edge techniques to discover and advance ground breaking biologics to the clinic, whether this is our own pipeline or that of our partners.
The industry is rapidly reducing the time to develop and manufacture new molecules, this is down to significant improvements in automation with many previously time consuming steps replaced with equipment that can analyze thousands of samples in minutes incredibly accurately. Throughout our entire process from early stage discovery, through cell line development and process development and to fill finish we have adopted the very latest technology to ensure we can offer the best timelines and most comprehensive analytics to generate the highest quality biologic drugs, our new brand represents our commitment to this innovation.”
Dr Windisch, continued “We are also launching our new value proposition, “We Care”, this represents our unwavering dedication to the patients that need our products and our commitment to honesty and transparency in all our interactions. All our colleagues carry these values through all the work they do and in all our cooperation with partners. We all share the same goal – delivering safe and effective medicines to patients.”
The new brand and values launch come after a year of significant growth at Polpharma Biologics, it has brought its Utrecht research and development site, formerly Bioceros, and its Warsaw manufacturing site under the Polpharma Biologics brand, and significantly expanded its workforce by over 250 employees.
Much of the new recruitment has taken place at their new clinical and commercial manufacturing site in Warsaw, which began construction in 2018. It has reached a significant milestone with the installation of its first bioreactor suite which contains twin 2000 L SUBs. The suite is now under validation and will be suitable for the manufacture of clinical and commercial mammalian products, it is expected to be ready for its first production run in mid-2021. This is one of 5 manufacturing suites currently planned for the site which also contains research and process development laboratories.
Frank Ternes, Global Head of CDMO commented “The combination of our new brand and installation of new bioreactors brings us closer to our ambition to be an industry-leading biotechnology company, with a world-class offering to help partners take their products rapidly to market with the maximum chance of success. Polpharma Biologics now has the ability to offer a full range of solutions for both mammalian and microbial from discovery to commercial supply for both drug substance and drug product.”
-ENDS-
About Polpharma Biologics
Polpharma Biologics is a European biopharmaceutical company focused on the development and manufacture of biosimilar and novel biologic drugs. Polpharma Biologics operates across centers of excellence in Poland and the Netherlands providing fully integrated solutions along the biopharmaceutical value chain. Polpharma Biologics offers antibody discovery and optimization, cell line development, product and process development and clinical and commercial scale manufacturing to support the development of its proprietary portfolio of products and the provision of high quality contract development and manufacturing services to industry partners around the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005383/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HyperLight Introduces 145 GHz Reference Modulators to Enable 448Gbps per Lane Datacom and 260GBaud Telecom Development12.3.2026 14:03:00 CET | Press release
HyperLight Corporation, creator of the TFLN Chiplet™ platform, today announced the release of its 145 GHz Packaged Intensity Modulator (IM), expanding the company‘s high-speed modulator portfolio. The new device is designed for ultra-wide modulation bandwidth, high signal fidelity, and stable operation control, enabling 448 Gbps per lane intensity-modulated-direct-detection (IMDD), 260 GBaud coherent links, and broadband RF photonics systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312319685/en/ Fig. 1: HyperLight’s 145 GHz intensity modulator for 448Gbps per lane IMDD and 260GBaud coherent applications, with operational electro-optical bandwidth >145GHz, stable bias control, 0.8 mm-connector; available in O-, C-, and L-bands. As symbol rates and analog bandwidth requirements continue to rise across data center interconnects, AI-driven photonics infrastructure, and laboratory test environments, system architects in
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences12.3.2026 14:00:00 CET | Press release
Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acquisition enables Enodia to advance its understanding of Sec61 selectivity mechanisms, expanding biological and translational insights for faster progression toward key clinical milestones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312627573/en/ Under the terms of the purchase agreement between Enodia and Kezar, Kezar w
Adtran to showcase industry-leading open optical networking for the AI era at OFC 202612.3.2026 14:00:00 CET | Press release
News summary: Adtran will show how intelligent optical networks can scale infrastructure while controlling power, complexity and security risks Highlights include LiteWave800™, an ultra‑low‑power 800G pluggable transceiver, which sets a new 1pJ/bit benchmark for intra‑data center connectivity Adtran will participate in OIF multi‑vendor interoperability demos and present European‑led innovation through advanced research projects Adtran today announced that it will showcase its latest optical innovations at OFC 2026, taking place from March 15 to 19 in Los Angeles. The company will outline how intelligent, secure and power‑efficient optical networks are shaping the next phase of AI infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311958018/en/ Adtran’s optical networking technology is helping build the foundation for the AI era. At Adtran’s booth (1001), visitors can explore solutions spanning ultra‑low‑power
Wellesley Hills Financial Goes Global: New London and New York Hubs Signal Aggressive Expansion into Transatlantic Fintech M&A12.3.2026 13:00:00 CET | Press release
With the addition of industry veterans Barry Davis and Bill Shraga, WHF strengthens its cross-border capabilities and scales its specialized Merchant Portfolios platform to a national level. Wellesley Hills Financial (“WHF”), a premier fintech and payments-focused investment bank spanning the lower to upper middle market, today announced a series of senior appointments and geographic expansions that further scale its global advisory platform and deepens its capabilities across the payments and fintech ecosystems. The firm has appointed Barry Davis as Executive Advisor, based in London, added Managing Director Bill Shraga in New York, and expanded its payments consulting subsidiary, Merchant Portfolios (“MP”), with the addition of EVPs Lance McCord in North Carolina and Nolan Pittman in Arizona. Strengthening Transatlantic Connectivity Barry Davis joins WHF as the firm’s first London-based Executive Advisor, marking a significant milestone in WHF’s international expansion. His appointme
Prodalim Strengthens its Functional Platform to Enter the Fast-Growing Nutraceutical Market with the Acquisition of Sylvestre, a Market Leader in Botanical Extracts Based in Brazil12.3.2026 11:45:00 CET | Press release
The acquisition positions Prodalim to deepen its fast-growing functional beverage solutions offering, accelerate its expansion into the US functional ingredients market, and broaden its presence across emerging markets Prodalim, a global leader in juice and specialty ingredients solutions, announced today the acquisition of Sylvestre, a leading Brazilian producer of botanicals and functional extracts addressing the nutraceutical market. Sylvestre’s existing owners and management team will remain with the company and support its integration into Prodalim’s platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312584318/en/ Founded in 1992 in Brazil, Sylvestre is a trusted supplier of high-quality natural ingredients, specializing in botanical extracts, fruit powders, superfruits, teas, and unique functional plant-based solutions sourced from the rich and diverse Brazilian flora. With a portfolio of more than 200 natural
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom